Supernus (SUPN) insider sales: 10,235-share planned sale; $12.6M sold in past 3 months
Rhea-AI Filing Summary
Form 144 notice for SUPN (Supernus Pharmaceuticals, Inc.) shows an insider sale filing for common stock scheduled with Morgan Stanley Smith Barney. The filer reports proposing to sell 10,235 shares on 09/29/2025 with an aggregate market value of $481,352.05. The shares were acquired the same day (09/29/2025) via exercise of stock options and payment was in cash. The filing lists total shares outstanding of 56,073,088, which places the proposed sale at a very small fraction of outstanding stock. The notice also discloses multiple Rule 10b5-1 sales by Jack A. Khattar during August–September 2025 totaling 285,300 shares for combined gross proceeds of approximately $12,588,665.79. The filer certifies no undisclosed material adverse information and references Rule 10b5-1 plan representations.
Positive
- Securities were acquired by exercise of stock options and paid in cash, indicating clear title to the shares
- Planned sale size (10,235 shares) is a very small fraction of the 56,073,088 shares outstanding
Negative
- Substantial insider selling in Aug–Sep 2025: 285,300 shares sold under 10b5-1 plans for approximately $12,588,665.79, which may signal insider liquidity
- Frequent 10b5-1 trades by the same insider over a short period could be viewed negatively by some investors seeking insider confidence
Insights
TL;DR: Insider exercised options and plans a small sale; recent 10b5-1 sales totaled ~285k shares for ~$12.6M.
The filing indicates a routine insider exercise and planned disposition of 10,235 shares via Morgan Stanley on 09/29/2025, acquired and to be sold the same day for cash. Relative to the reported 56,073,088 shares outstanding, the proposed sale is immaterial in size. However, the series of Rule 10b5-1 sales by Jack A. Khattar over August–September 2025 amount to 285,300 shares and roughly $12.59 million in proceeds, which is a non-trivial pace of insider selling over the past quarter. This pattern merits monitoring but does not by itself confirm any change in fundamentals.
TL;DR: Disclosure aligns with Rule 144/10b5-1 norms; seller attests no undisclosed material information.
The document follows procedural requirements for reporting a proposed sale following option exercise and includes Rule 10b5-1 plan sales history. The signature/attestation language confirms the filer represents no knowledge of undisclosed material adverse information. From a governance standpoint, the filing is complete in the sections provided, showing use of a broker and structured plan-based sales, which tends to mitigate concerns about opportunistic timing but still reflects meaningful insider liquidity in recent months.